PubRank

Should hepatic resection be recommended to patients with hepatocellular carcinoma and portal vein invasion?

PubWeight™: 0.76‹?›

🔗 View Article (PMID 27475616)

Published in J Hepatol on July 27, 2016

Authors

Hui-Lin Wang1, Alessandro Cucchetti2, Jian-Hong Zhong3, Xin-Ping Ye4, Jian-Hong Gu5, Liang Ma6, Ning-Fu Peng7, Le-Qun Li6

Author Affiliations

1: Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, PR China.
2: Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Bologna 40138, Italy.
3: Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, PR China. Electronic address: zhongjianhong66@163.com.
4: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, PR China.
5: Yangzhou University & Jiangsu Co-Innovation Center, Yangzhou 225009, PR China.
6: Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, PR China.
7: Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, PR China. Electronic address: pengningfu@163.com.

Articles citing this ↘

Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clin (2016) 0.76

New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol (2017) 0.75

Articles by these authors ⇆

Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget (2017) 0.75

Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the barcelona clinical liver cancer treatment algorithms: A review and update. Oncotarget (2017) 0.75

Adipocyte-derived exosomes promote lung cancer metastasis by increasing MMP9 activity via transferring MMP3 to lung cancer cells. Oncotarget (2017) 0.75